Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences Inc. is advancing its clinical-stage product candidates, exemplified by the promising prospects for darovasertib in combination with crizotinib, which management believes could have a hazard ratio (HR) of 0.6 or lower, leading to swift market uptake. The company's ongoing enthusiasm for its product pipeline, particularly the combinations of its PARG inhibitor IDE161 with IDE849 and other antibody-drug conjugates (ADCs), positions it favorably for future developments and potential approvals. Management's confidence in upcoming studies, including a registrational study in small cell lung cancer (SCLC) and the rapid enrollment of participants, underscores the robust clinical activity anticipated from their precision medicine strategies.

Bears say

IDEAYA Biosciences reported a net loss of $83.3 million, or $0.94 per share, which was slightly better than the projected loss of $1.05 per share, primarily due to collaboration revenue from Servier. The company faces significant risks related to research and development, regulatory approvals, and potential commercial challenges, particularly with its key product candidates darovasertib, IDE397, and IDE849, which may not achieve sales estimates or could encounter competition from emerging therapies. Additionally, the possibility of dilutive financing further exacerbates concerns regarding the company's financial health and market outlook.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.